The AACR-Johnson & Johnson Lung Cancer Innovation Science Grants represent a joint effort to address the need for promoting and supporting collaborative cancer research. Moreover, the research area includes digital therapeutics and smoking cessation biomarkers/behavioral phenotyping, to bolster the understanding of how to intercept the lung cancer. As such the American Association for Cancer Research (AACR) is accepting the application for Lung Cancer Innovation Grants.
ACCR will accept proposals for new ideas and innovative approaches that have direct application and relevance to lung cancer prevention and interception. Moreover, the proposed research should be translational in nature. Also, it should include a clinical component with an endpoint relevant to improving the detection or treatment of lung cancer.
In association with Johnson & Johnson, AACR is providing a subsidiary grant of $1,000,000 to successful candidates for innovation in treatment and interception of Lung Cancer.
To apply for the AACR-Johnson & Johnson Grants, candidates must submit the online application form before the deadline. Along with the online application form, the candidates will further require to submit necessary documentation including CVs of all associated personnel; Proposal for the project and other necessary documentation.
AACR requires applicants to submit an electronic application by 1:00 pm, U.S. Eastern Time on Friday, July 19, 2019